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ABSTRACT
In colorectal cancer patients, chromosomal rearrangements involving NTRK1 
gene (encoding the TRKA protein) are shown in a small subset of patients and are 
associated with the constitutive activation of the kinase domain of TRKA. In turn, 
activated TRKA-fusion proteins are associated with proliferation and survival in 
colorectal cancer tumors. 
Here we report the identification and functional characterization of a new SCYL3-
NTRK1 fusion gene in a 61-year-old colorectal cancer  patient. To our knowledge, this 
fusion protein has never been previously documented in oncological patients. We 
show that this novel fusion is oncogenic and sensitive to TRKA inhibitors.
As suggested by other pieces of evidence, entrectinib - an orally available pan-
TRK, ROS1 and ALK inhibitor - may have particular efficacy in patients with NTRK 
rearrangements. Therefore, screening for rearrangements involving NTRK genes 
may help identifying a subset of patients able to derive benefit from treatment with 
entrectinib or other targeted inhibitors.
INTRODUCTION
Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer worldwide, with more than one million 
new cases per year, and represents a major cause of cancer-
related death [1]. Patients with advanced colon cancer are 
primarily treated with fluoropyrimidine-based systemic 
chemotherapy with or without irinotecan or oxaliplatin. 
Despite intense efforts dedicated to the identification of 
new and more effective therapies, many patients still have 
a poor treatment outcome. Although targeted agents such 
as cetuximab, panitumumab, bevacizumab, aflibercept, 
ramucirumab and regorafenib, introduced into the clinical 
practice during the last decade, have conferred incremental 
survival gains [2, 3] the identification of novel tumor 
targets and new targeted therapies is warranted to ensure a 
better long-term clinical benefit.
We originally reported the identification of a 
chromosomal rearrangement involving NTRK1 (encoding 
the TRKA protein) and the TPM3 gene in the KM12 
colorectal tumor cell line and showed for the first time that 
the resulting TPM3-TRKA fusion protein is an oncogenic 
driver sensitive to TRKA inhibitors. We also showed by 
screening colorectal tumor samples that this rearrangement 
is present with approximately 1% frequency in CRC and 
that IHC with anti TRKA antibodies can be successfully 
                                Research Paper
Oncotarget55354www.impactjournals.com/oncotarget
applied to facilitate the initial screening of rearranged 
tumors [4]. These findings were further strengthened 
through genetic screenings performed on large collections 
of CRC specimens, confirming the presence of NTRK1 
rearrangements in 0.5–2% of CRC patients [5, 6]. 
Although many different NTRK1 rearrangements have 
been already identified in a wide range of solid tumors (see 
www.ntrkfusions.com), only a limited number of fusion 
partners has been detected so far in CRC (TPM3-NTRK1, 
LMNA-NTRK1 and TPR-NTRK1 fusion genes) [5, 7, 8]. 
All these rearrangements result in the expression of fusion 
proteins harboring a constitutively activated TRKA kinase 
domain as a consequence of protein dimerization due to 
the presence of a coiled-coil domain in the N-terminal 
sequence of the partner protein. Preclinical data 
demonstrated that activated TRKA-fusion proteins are 
associated with/responsible for proliferation and survival 
in these subsets of CRC tumors [4, 6]. Importantly, we 
reported the first evidence of clinical benefit achieved with 
the TRKA-targeted agent entrectinib in a CRC patient 
bearing a LMNA-NTRK1 positive tumor, providing clinical 
validation of activated TRKA as a target in CRC [7].     
Based on these promising preclinical data and phase 
I results, TRKA-selected CRC patients are currently being 
enrolled in the open-label, multicenter global phase II 
basket study of entrectinib, an orally available pan-TRK, 
ROS1 and ALK inhibitor.
The molecular screening, aimed to select TRKA-
positive patients for the enrollment in the above-mentioned 
trial, led to the discovery of a CRC patient harboring a 
novel NTRK1 gene rearrangement consisting of a fusion 
between the NTRK1 and SCYL3 genes. Here we report the 
identification and characterization of the resulting SCYL3-
NTRK1 fusion gene that, to our knowledge, has not been 
previously reported in cancer patients.
RESULTS
The patient was a 61-year-old female diagnosed in 
February 2015 with adenocarcinoma of the right colon, 
infiltrating the pancreas. The patient progressed early on 
two standard treatment lines (FOLFOX-panitumumab 
followed by FOLFIRI-aflibercept). As part of a wide 
phase I screening program at our institutions (Fondazione 
IRCCS Istituto Nazionale dei Tumori and Niguarda Cancer 
Center, Milan, Italy), a deeper molecular characterization 
of the patient’s primary tumor was performed. Results 
indicated that the tumor was wild type for RAS, BRAF, 
and EGFR with a high microsatellite instability (MSI-H) 
profile. At the time of progression to second line therapy 
(October 2015), the patient underwent endoscopic biopsy 
of the right-sided tumor mass as part of the pre-screening 
procedures for the enrollment in the phase I clinical trial 
ALKA-372-001 (EudraCT Number: 2012.000148-88) [9]. 
The tumor was tested by immunohistochemistry (IHC) for 
TRKA, ROS1 and ALK proteins whose expression may 
indicate the result of a genetic alteration. The IHC analysis 
revealed strong positivity for TRKA protein with a clear 
cytoplasmic distribution suggesting a potential aberrancy 
of NTRK1 gene. The observed immunoreactivity was 
uniformly characterized by a basic faint cytoplasmic 
staining associated with a more intense staining organized 
in irregular or ovoidal clods, preferentially localized 
around the nuclei (Figure 1A). The size of the clods was 
highly variable and irregular in shape. Intriguingly, this 
immunoreactivity pattern appeared very different from 
the one observed in the patient harboring LMNA-NTRK1 
rearrangement, which was a moderate cytoplasmic staining 
associated  with a more intense perinuclear staining as 
well as from the pattern found in TPM3-NTRK1 bearing 
KM12 cells, where a diffused cytoplasmic staining could 
be appreciated (Supplementary Figure 2) [4, 7].  
In order to verify if the detected TRKA expression 
was indeed the result of a genomic rearrangement, 
fluorescence in situ hybridization (FISH) analysis was 
performed using a commercial break-apart probe for the 
NTRK1 gene (Abnova). Results from this analysis showed 
the presence of break-apart signal, with separate green and 
orange signals in 90% of analyzed nuclei, confirming the 
presence of a NTRK1 rearrangement (Figure 1B). The 
FISH pattern was similar to the one previously detected 
in the KM12 cell line.
Since the immunohistochemical staining of our 
sample was strikingly different from the one previously 
observed in the KM12 cells, we performed a second 
FISH analysis with customized break-apart probes 
(Empire Genomics), initially used for the identification 
of LMNA-NTRK1 gene fusion in another CRC sample 
[7]. This further FISH analysis showed that the red 
centromeric signal from the break-apart probe was absent 
in 68% of analyzed nuclei, confirming once again the 
presence of a genetic alteration involving the NTRK1 
gene (Figure 1C). The observed discrepancy between 
the two hybridization patterns may be due to the specific 
features of the probes used in the two FISH analyses. In 
particular the loss of the red-labeled centromeric probe 
observed in the second analysis only can be explained 
with the different length of the centromeric probe. 
Indeed, differences in FISH probe design have previously 
been shown to complicate the evaluation of the small 
interstitial deletion that forms the GOPC-ROS1 fusion 
[10]. Taken together, these observations suggested the 
presence of a novel NTRK rearrangement and prompted 
further molecular characterization for the identification 
of the N-terminal partner gene. An RNA-based anchored 
multiplex polymerase chain reaction Next Generation 
Sequencing (NGS) assay, customized for the detection 
of rearrangements of selected tyrosine kinases and for 
simultaneous identification of the fusion partner, was 
applied [11]. This approach allowed the identification of 
a new NTRK1 rearrangement resulting from an inversion 
within chromosome 1 fusing exons 1–11 of the SCY1 
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Figure 1: Histologic, immunohistochemical, and fluorescence-in-situ hybridization analyses of the case presented. 
Immunohistochemical and Fluorescent-In-Situ Hybridization (FISH) images of poorly differentiated CRC. In immunohistochemical 
assays Panel (A), magnification 100X, whole neoplastic cells are stained by TRKA. The observed staining is characterized by a basic 
faint uniformly cytoplasmic staining associated to more intense staining organized in irregular round or ovoidal dark bodies (Insert A1, 
star: magnification 400X) preferentially distributed around nucleus. Dark bodies’ size is variable ranging from tiny dot  spherules-like to 
bigger bodies with irregular size and shape. The bigger bodies are fused in coarse ovoid structure surrounding nucleus (Insert A2, arrow; 
magnification 400X). In panel (B), FISH analysis using the Abnova Break Apart probes showed the presence of one fusion signal along 
with separate green and orange signals suggesting the presence of a rearrangement of NTRK1 gene. In Panel (C), FISH analysis performed 
with customized break-apart probes from Empire Genomics showed the green signal only, corresponding to the telomeric part of  the break 
apart probe  (white arrows inset), while the red signal corresponding to the centromeric probe (which covers the NTRK1 gene) is missing. 
Magnification of images: 1000X or 630X as indicated.
Oncotarget55356www.impactjournals.com/oncotarget
Like Pseudokinase 3 (SCYL3) gene with exons 12–17 
of NTRK1 gene (Figure 2). No other NTRK1 fusion 
transcripts were observed.  
As this rearrangement has never been previously 
described, to formally demonstrate its oncogenic potential, 
we transfected IL3-dependent Ba/F3 cells (a murine 
pro-B system that does not possess any endogenous 
human TRKA expression) with SCYL3-NTRK1 cDNA 
construct (Supplementary Figure 1). As consequence of 
the expression of the corresponding TRKA-containing 
fusion protein, Ba/F3 cells acquired IL3-independent 
proliferation capability, demonstrating that SCYL3-
NTRK1 is indeed an oncogenic driver. These transformed 
cells were used to test and compare the potency of 
TRK inhibitors [6, 9]. Treatment with three different 
TRK inhibitors strongly affected the proliferation of 
Ba/F3-SCYL3-NTRK1 whereas no growth inhibition 
was observed in the parental Ba/F3 cells or the Ba/F3-
SCYL3-NTRK1 cells grown in the presence of IL-3 [12]. 
Entrectinib was found to be the most potent compound 
inhibiting the proliferation of TRKA-driven cells with an 
IC50 value of 1.5 nM. Other TRK inhibitors LOXO-101 
and Crizotinib were also able to decrease the proliferation 
of Ba/F3-SCYL3-NTRK1 cells with IC50 values of 11.2 
nM and 160 nM, respectively (Figure 3A). The mechanism 
of action of entrectinib was confirmed by flow cytometer 
analysis of Propidium Iodide (PI) stained cells 18-hour 
post entrectinib treatment. Consistent with previous 
publication [13], entrectinib induced cell cycle arrest at 
G0/G1 (Figure 3C). Furthermore, caspase 3/7 activities 
were peaked between 24 to 30 hours upon entrectinib 
treatment, at as low as 3.7 nM (Figure 3D).
Western Blot analysis demonstrated a dose-dependent 
modulation of TRKA phosphorylation with concomitant 
inhibition of phosphorylation of the downstream signal 
transducer PLCγ (Figure 3B), consistent with prior studies 
[13]. Crizotinib was also able to modulate TRKA signaling, 
although at significantly higher doses, in agreement with its 
calculated IC50.
DISCUSSION
The identification of oncogenic fusions resulting 
from chromosomal rearrangements in many different 
tumor types represents an important opportunity for 
novel therapeutic strategies.  This is definitely true 
for lung adenocarcinoma, as the introduction into the 
clinical practice of therapeutic approaches based on the 
specific targeting of activated kinases has dramatically 
changed the clinical outcome of many patients [14, 15]. 
By contrast, in a high un-met medical need such as 
CRC, the era of targeted therapy coupled with positive 
predictive biomarkers, is still in its infancy. For many 
years molecular analyses performed in metastatic CRC 
patients have been aimed mainly to identify RAS or BRAF 
mutations that are associated with the lack of response 
to anti-EGFR treatment [16, 17]. The identification of 
positive predictive biomarkers to be exploited for targeted 
therapeutic approaches in CRC, such as HER2 for dual 
HER2 blockade, MSI-H for immune checkpoint inhibitors, 
BRAF for dual/triple inhibition strategies and MGMT 
methylation for alkylating agents [18–21], represents a 
paradigm shift for the future treatment landscape [22]. The 
identification of chromosomal rearrangements involving 
NTRK1 as a low frequency event in a subset of CRC 
patients is a relatively recent finding [23]. So far limited 
efforts have been dedicated to the screening of a high 
number of cases in order to define the prevalence and the 
relevance of these findings for CRC patient population. 
The clinical validation of NTRK1 rearrangements as 
targets for therapy in CRC will spur the molecular 
screening of an increasing number of patients, widening 
Figure 2: Identification of the SCYL3-NTRK1 gene rearrangement. Schematic representation of the SCYL3-NTRK1 
rearrangement. Exons involved in the rearrangement are represented by colored boxes: SCYL3 is reported in green, while NTRK1 is 
reported in red. The sequence spanning the junction site is shown in detail.
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the opportunity for the application of TRKA-targeted 
agents into the clinical practice.
In our laboratories, the presence of NTRK1 
rearrangements is routinely evaluated by IHC in all CRC 
tumors in the course screening for patients’ enrollment 
into clinical trials with entrectinib. This screening 
previously resulted in the identification of two oncogenic 
fusions, TPM3-NTRK1 and LMNA-NTRK1, that were 
fully characterized. We also demonstrated that the 
patients harboring TRK rearrangements derive clinical 
benefit from the treatment with entrectinib, a specific 
TRK inhibitor [9]. Here we report the identification of 
a new chromosomal rearrangement involving NTRK1 
that results in the generation of the chimeric SCLY3-
TRKA fusion protein. Despite the significant number of 
different fusion partners that has already been identified 
for NTRK1 in solid tumors, to our knowledge this is the 
first time that the SCYL3 gene is found to be involved 
in a rearrangement with NTRK1 or any other kinase 
gene. It will be interesting to understand if this fusion is 
specific to CRC or it is also present in other tumor types, 
such as non small cell lung cancer, papillary thyroid 
carcinoma and glioblastomas, where multiple NTRK1 
rearrangements have already been identified [23–25].
SCYL3, also known as PACE-1, a gene widely 
expressed in a variety of tissues, encodes for a protein 
whose function is still poorly understood. The full-length 
protein is able to bind to ezrin through a C-terminal 
domain determining its localization at the level of 
lamellipodia, a specialized cell structure that facilitates 
cell advancement across a substrate, where it probably 
plays a role in cell spreading and motility. In addition 
the N-terminal region contains a myristoylation motif 
that is responsible for its association with the Golgi 
apparatus. Intriguingly, SCYL3 protein contains a kinase 
domain but any attempt to demonstrate its intrinsic kinase 
activity failed so far, suggesting that it should be probably 
considered a pseudokinase [26].
As the SCYL3 gene maps to chromosome 1q23.3-4 
(1q24.2 on NCBI, OMIM, Gene Cards) we hypothesize 
Figure 3: Mechanism of action of entrectinib. Confirmation that the SCYL3-NTRK1 fusion gene can be targeted by TRK inhibitors. 
(A) Comparison of anti-proliferation activities of 3 tyrosine kinase inhibitors in Ba/F3-SCYL3-NTRK1 cell line. (B) Western blot analysis 
of the changes in phosphorylation levels of TRKA and its downstream transducer PLCγ 2 hours post entrectinib and crizotinib treatment 
in Ba/F3-SCYL3-NTRK1 cells. (C) Cell cycle analysis of Ba/F3-SCYL3-NTRK1 treated with 3 and 10 nM of entrectinib for 18 hours 
compared to untreated cells. (D) Relative caspase 3/7 activities in Ba/F3-SCYL3-NTRK1 cells treated with increasing concentrations of 
entrectinib over time.
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that the generation of the fusion gene SCYL3-NTRK1 
is a consequence of an intrachromosomal inversion 
that juxtaposes the first 11 exons of SCYL3 to a portion 
encompassing exon-12-17 of NTRK1. As a consequence 
of this fusion event SCYL3 loses the C-terminal 
sequence responsible for ezrin binding but it maintains 
its myristoylation motif. The expected localization of the 
resulting fusion protein SCYL3-TRKA at the level of 
the Golgi apparatus is compatible with the characteristic 
punctate intracellular staining pattern observed by 
immunohistochemical analysis [27]. The in vitro data 
clearly demonstrate that the SCYL3-NTRK1 fusion gene 
is oncogenic and that the resulting fusion protein has 
constitutive kinase activation. Targeted inhibitors, in 
particular entrectinib, strongly inhibit the SCYL3-TRKA 
phosphorylation leading to cell growth inhibition and 
confirming the role of the expressed fusion protein as driver 
for proliferation. Our data demonstrate that entrectinib 
represents an important potential opportunity for the 
treatment of patients whose tumors harbor this new NTRK1 
rearrangement. Unfortunately, the clinical conditions of this 
patient rapidly degraded because of tumor progression and 
it was not possible to treat her with entrectinib.  
However, consistent with prior published reports 
of tumor growth inhibition in NTRK1 rearranged patients 
treated with entrectinib [7–9], our data showed that this drug 
has a significant therapeutic potential against newly identified 
NTRK1 gene rearrangements. Consequently, the screening of 
CRC for the detection of gene rearrangements involving the 
NTRK1, NTRK2 and NTRK3 genes has the ability to identify 
a limited subset of patients able to derive benefit from 
treatment with entrectinib or other targeted inhibitors.
MATERIALS AND METHODS
Immunohistochemistry 
TRKA protein expression was assessed in 
formalin-fixed paraffin-embedded (FFPE) tumor tissue 
sections using a rabbit monoclonal antibody (clone 
EP1058Y; Epitomics, Burlingame, CA) that recognizes 
the carboxyl-terminus of the protein. Briefly, three 
micron-thick sections were reacted for 30 min with the 
anti-TRKA antibody used at 1:200 working dilution 
and then incubated with a commercially available 
detection kit (EnVision™ FLEX+, Dako, Glostrup, 
Denmark) following the manufacturer’s instructions 
and previously refined IHC methods. The specificity 
of all reactions was checked replacing the primary 
antibody with a non-related mouse immunoglobulin 
at comparable dilutions or using normal serum alone, 
Positive and negative controls were used as appropriate 
KM12 cell line, known to carry a TPM3-NTRK1 gene 
rearrangement, was used as positive control.
FISH analysis for NTRK1
In order to identify possible rearrangements 
involving the NTRK1 gene, dual colour FISH analysis 
was performed on 3 µm-thick sections of FFPE tumor 
tissue using a commercially available, specific break-apart 
probe kit (Abnova) and following the manufacturer’s 
instructions. In addition customized break-apart probes, 
(Empire Genomics), previously described, were used 
[7]. Briefly, NTRK1 FISH analysis was conducted 
using 10 μl mix-probe made up by 1 ul BAC (Bacterial 
Artificial Chromosome) genomic probe RP11-349I17 
(1q23.1) (206 kb) labelled in SpectrumOrange (Empire 
Genomics), 1 ul BAC (Bacterial Artificial Chromosome) 
genomic probe RP11-1038N13 (1q23.1) (129 kb) 
labelled in SpectrumGreen (Empire Genomics), 1 ul of 
sterile water and 7 ul of hybridisation buffer (Empire 
Genomics). Probes and target DNA of specimen were co-
denatured in HYBRite System (DakoGlostrup, Denmark) 
for 5 min at 75°C and then hybridized overnight at 
37°C. Slides were washed with post-hybridisation 
buffer (DakoGlostrup, Denmark) (73°C for 2 min) and 
counterstained with 4,6-diamino-2phenylindole (DAPI 
II; Vysis, Vysis, Downers Grove, IL. USA). A sample 
was scored as positive if rearrangements of NTRK1 
gene were detected in at least 15 of 100 analysed nuclei. 
Healthy tissue was used as internal negative control. 
Fluorescent in situ hybridisation signals were evaluated 
with a Zeiss Axioscope Imager Z1 (Zeiss,Gottingen, 
Germany). Images for documentation were captured with 
CCD camera and processed using the MetaSystems Isis 
software.
Targeted RNA sequencing
Gene rearrangements/fusions were analyzed by 
targeted RNA sequencing, using an anchored multiplex PCR 
(AMP) method (ArcherDx, Inc.) as previously described 
[11]. Briefly, a custom panel was generated to focus on 
determination of gene rearrangements in NTRK1, NTRK2, 
NTRK3, ROS1, and ALK and RET genes (encoding the 
TRKA, TRKB, TRKC, ROS1, ALK and RET proteins) 
along with associated housekeeping genes to assess RNA 
fragmentation. The AMP method allows for improved 
sensitivity to novel fusion partners due to an initial adapter 
ligation step that facilitates priming without de novo 
knowledge of the gene rearrangement partner and limitations 
from the small fragments generated in FFPE tissues. 
This study was performed according to the clinical 
standards of the 1975 and 1983 Declaration of Helsinki 
and was approved by the Ethical Committee of Fondazione 
IRCCS Istituto Nazionale dei Tumori  (n° INT 48/16).
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Functional studies of SCYL3-NTRK1 fusion gene 
cDNAs (see supplementary data) encoding the 
SCYL3-NTRK1 fusion protein was inserted into the 
lentiviral vector pVL-EF1a-MCS-IRES-Puro (BioSettia, 
San Diego, CA) and introduced into the murine, IL-3 
dependent, pro-B  Ba/F3 cells (DSMZ) [12]. Ba/F3-
SCYL3-NTRK1 stable cells only proliferate without the 
need of IL-3. Proliferation assays were conducted with 
these cells with various concentrations of entrectinib 
(synthesized by Ignyta), LOXO-101 (synthesized by 
Ignyta) and crizotinib (purchased from Sellekchem). 
Plates were incubated at 37°C in 5% CO2 for 72 hours, 
after which cell viability was assessed by measuring 
ATP content using Cell Titer-Glo® Luminescent Cell 
Viability assay (Promega). IC50s were calculated using the 
4-parameter variable slope curve fit (GraphPad Prism).
For Western blot analysis, cell lysates were prepared 
in 1X RIPA buffer (EMDMillipore) with protease and 
phosphatase inhibitors (EMDMillipore) 2 hours post 
treatment. The protein lysates were analyzed with SDS-
PAGE gels (Thermofisher) and transferred to the PVDF 
membrane using iBlot2 (Thermofisher). The western 
blot analysis was performed using the primary antibodies 
(phosphorylated/total TRKA and PLCγ, and α-tubulin) from 
Cell Signaling Technology and the HRP-labeled secondary 
antibodies were purchased from LI-COR. The reactive 
bands were developed by ECL Prime reagent (Amersham) 
and images were captured by ChemiDoc (Bio-Rad).
To evaluate the effect of entrectinib on the cell cycle, 
cells were treated with various concentrations of entrectinib 
for 18 hours and fixed in cold 70% ethanol, and stained 
by Propidium Iodide (PI/RNase Staining Buffer (BD 
Bioscience, cat#550825)). The cell cycles were analyzed 
using a CytoFlex flow cytometer (Beckman Coulter).
To confirm the induction of apoptosis by entrectinib, 
cells were treated with various concentrations of 
entrectinib and Caspase-3/7 Reagent (IncuCyte, #4440) 
was added to all samples. Live images (Phase and green 
fluorescent channels) were collected at 4-hour intervals 
over 40 hours. Active Caspase-3/7 activities were 
normalized to cell numbers.
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